| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pet Pharm Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$40.45 |
| 52 Week High | NT$42.20 |
| 52 Week Low | NT$27.50 |
| Beta | 0 |
| 11 Month Change | 7.72% |
| 3 Month Change | 33.06% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.76% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| 7762 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.5% | -0.5% | -2.4% |
| 1Y | n/a | 8.2% | 36.3% |
Return vs Industry: Insufficient data to determine how 7762 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 7762 performed against the TW Market.
Price Volatility
| 7762 volatility | |
|---|---|
| 7762 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in TW Market | 8.8% |
| 10% least volatile stocks in TW Market | 2.9% |
Stable Share Price: 7762 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: Insufficient data to determine 7762's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | n/a | www.petpharmbio.com |
Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules.
Pet Pharm Biotech Co., Ltd. Fundamentals Summary
| 7762 fundamental statistics | |
|---|---|
| Market cap | NT$1.64b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 7762 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7762 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7762 perform over the long term?
See historical performance and comparison